NCT06045260View on ClinicalTrials.gov

"Receptor Radionuclide Therapy With 177Lu-DOTATOC"

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 13, 2023

Primary Completion Date

February 28, 2025

Study Completion Date

January 31, 2027

Conditions
Neuroendocrine TumorsParagangliomaPheochromocytoma
Interventions
DRUG

177Lu-DOTATOC

Administration of 4 cycles of therapy with 7.4 Gbq Dose for No risk factors Arm and 5.5 Gbq Dose for Risk Factor Arm. Both through slow intravenous infusion in 30 minutes with a dedicated pump system.

Trial Locations (2)

47014

RECRUITING

"IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l.", Meldola

47521

NOT_YET_RECRUITING

"AUSL Romagna - Ospedale M. Bufalini", Cesena

All Listed Sponsors
lead

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

OTHER